Alvotech

ALVO

Market cap $1.45B

ALVO Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Dec. 2, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.

ALG, ALVO and CBRL have been added to the Zacks Rank #5 (Strong Sell) List on Nov. 28, 2025.

SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.

REYKJAVIK,  ICELAND (November 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Commission (EC) has approved AVT03 as a biosimilar to Prolia® and Xgeva® (denosumab).

ALVO, AKZOY and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2025.

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alvotech ("Alvotech" or the "Company") (NASDAQ: ALVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission (EC) has granted marketing authorizations in the European Economic Area (EEA) for Gobivaz®, Alvotech's biosimilar to Simponi® (golimumab).

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission (EC) has granted marketing authorizations in the European Economic Area (EEA) for Gobivaz®, Alvotech's biosimilar to Simponi® (golimumab).

NEW YORK--(BUSINESS WIRE)---- $ALVO #investor--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Alvotech (“Alvotech” or the “Company”) (NASDAQ:ALVO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On November 3, 2025, the Company received a complete response letter (“CRL”) from the FDA for its biologics license a.

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.